Loading...
Bienvenue sur la collection HAL du laboratoire de BECCOH
Quelques conseils pour une publication "idéHALe"
• Pensez à respecter la signature institutionnelle
Université Paris-Saclay, UVSQ, BECCOH, 92104, Boulogne-Billancourt, France..
• Participez à l'accès ouvert
N'attendez pas : dès que votre article est en ligne, déposez dans Hal sa version acceptée pour publication et indiquez un embargo de 6 mois.
La loi pour une république numérique vous autorise en effet à partager cette version 6 mois après publications, quelque-soit l'éditeur
Plus d'informations Archives Ouverte : quid de mes droits d'auteurs ?
• Vous souhaitez disposer d'une page web référençant toutes vos publications ?
Créez vous en 5 minutes un idHal et un CVHAL
N'hésitez pas à nous contacter pour toutes questions,
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
Dernières Publications en accès ouvert dans Hal
-
Paul Takam Kamga, Marie Mayenga, Louise Sebane, Adrien Costantini, Catherine Julie, et al.. Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2024, 188, pp.107447. ⟨10.1016/j.lungcan.2023.107447⟩. ⟨hal-04517531⟩
-
Robin Zagala, Nicolas Meyer, Philippe Saiag, Nora Kramkimel, Celeste Lebbe, et al.. Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM network. Journal of the European Academy of Dermatology and Venereology, In press, ⟨10.1111/jdv.20155⟩. ⟨hal-04626767⟩
-
Alexandra Kachaner, Raphaèle Seror, Fleur Cohen Aubart, Julien Henry, Thierry Lazure, et al.. Complete remission after a single bisphosphonate infusion in isolated bone Langerhans cell histiocytosis lesion: a case report and a narrative review of the literature. JBMR Plus, 2024, 8 (5), pp.ziae043. ⟨10.1093/jbmrpl/ziae043⟩. ⟨hal-04626829⟩
-
Johanne Seguin, Mostafa El Hajjam, Josette Legagneux, Sarah Diakhaby, Nathalie Mignet, et al.. Radiofrequency Combined with Intratumoral Immunotherapy: Preclinical Results and Safety in Metastatic Colorectal Carcinoma. Pharmaceutics, 2024, 16 (3), pp.315. ⟨10.3390/pharmaceutics16030315⟩. ⟨hal-04626840⟩
-
Julie Lecuelle, Caroline Truntzer, Debora Basile, Luigi Laghi, Luana Greco, et al.. Machine learning evaluation of immune infiltrate through digital tumour score allows prediction of survival outcome in a pooled analysis of three international stage III colon cancer cohorts. EBioMedicine, 2024, 105, pp.105207. ⟨10.1016/j.ebiom.2024.105207⟩. ⟨hal-04626841⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. European Journal of Cancer, 2023, 193, pp.113252. ⟨10.1016/j.ejca.2023.113252⟩. ⟨inserm-04209605⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023. European Journal of Cancer, 2023, 193, pp.113251. ⟨10.1016/j.ejca.2023.113251⟩. ⟨inserm-04210036⟩
Mots clés
Diagnosis
Targeted therapy
Safety
Antibody-drug conjugate
ALK rearrangement
Trametinib
BRAFV600E mutation
Osimertinib
Children
Survival
Cemiplimab
BRAF V600E
Cutaneous squamous cell carcinoma
Radiofrequency ablation
Staging
Wnt
Advanced melanoma
Immunohistochemistry
Mesenchymal stromal cells
ALK
Anti-Tumor pharmacology
AZD9291
Cancer
Anti-PD1
Merkel cell carcinoma
Abscopal effect
Adjuvant FOLFOX
Locally advanced
Beta-catenin
Treatment
Androgen insensitivity
Prognostic
Circulating tumor DNA
Body mass index
Polyomavirus
Plasma
Colorectal cancer
Colorectal carcinoma
Non-small cell lung cancer
Acute generalized exanthematous pustulosis
Biomarker
Systemic therapy
Adjuvant therapy
Circulating cell-free DNA
Prevention
AML
Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy
Anti-PD-1 antibody
ACTH
Anti-CTLA-4
Adverse events
Advanced
Immune checkpoint inhibitor
Cancer bronchique non à petites cellules
2-chlorodeoxyadenosine
Immunotherapy
Assisted reproductive techniques
ADN tumoral circulant
Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian
Gastric bypass
Antineoplastic agents
Abdominal pain
Sonic Hedgehog
Surgical excision
Anti-PD-1
BRAFV600E
BRAFV600-mutant melanoma
BRAF
Resistance
Crizotinib
Molecular targeted therapies
Follow-up
Bariatric surgery
Immunomodulation
Chemoresistance
Histiocytosis
Radiotherapy
Nivolumab
Anti-PD1 blockade
Prognosis
Biliopancreatic diversion
Dabrafenib
Lung adenocarcinoma
Langerhans cell histiocytosis
TNM classification
Chemotherapy
BRAF V600-mutation
Melanoma
Bisphosphonates
EGFR
Metastatic cSCC
Invasive cutaneous squamous cell carcinoma
Adjuvant
Colon cancer
Allelic imbalance
Oncology
Metastatic
Biomarkers
Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation
Liver metastases